Banco BTG Pactual S.A. Acquires New Holdings in Insmed Incorporated (NASDAQ:INSM)

Banco BTG Pactual S.A. purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,240 shares of the biopharmaceutical company's stock, valued at approximately $576,000.

Several other hedge funds also recently made changes to their positions in INSM. Steward Partners Investment Advisory LLC boosted its holdings in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its position in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in Insmed during the 4th quarter worth about $47,000. Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the fourth quarter valued at approximately $86,000.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company's stock, valued at approximately $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. Bank of America upped their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Price Performance

INSM stock traded up $0.30 during midday trading on Friday, reaching $77.99. The company had a trading volume of 950,343 shares, compared to its average volume of 2,230,931. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The stock has a 50 day moving average price of $78.18 and a 200-day moving average price of $73.99. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market capitalization of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.